Bristol-Myers Squibb(US:BMY) Prnewswire·2025-10-17 14:00Core Insights - SystImmune Inc. and Bristol Myers Squibb announced the first safety and efficacy data from the global phase I US-Lung-101 study of iza-bren, a bispecific antibody-drug conjugate targeting EGFR and HER3, presented at the ESMO Congress 2025 [1][5] Study Results - The study evaluated 107 patients with advanced solid tumors, primarily those with heavily pre-treated metastatic or unresectable non-small cell lung cancer (NSCLC) [2] - At the data cut-off on July 23, 2025, 55% of patients receiving 2.5 mg/kg of iza-bren showed a confirmed response, with a median progression-free survival of 5.4 months [3] - The most common side effects were blood-related, such as neutropenia, which were manageable and did not lead to serious complications [2] Ongoing Research - Global registrational studies for first-line metastatic triple-negative breast cancer (TNBC), second-line metastatic EGFR-mutated NSCLC, and second-line metastatic urothelial cancer are ongoing, with plans for studies in other indications [4] Company Statements - SystImmune's Chief Medical Officer highlighted the consistent efficacy of iza-bren in a heavily pre-treated global population, supporting its potential as a treatment option across multiple tumor types [5] - Bristol Myers Squibb expressed commitment to developing innovative medicines that improve outcomes for patients with difficult-to-treat cancers, reinforcing confidence in iza-bren's potential [5] Product Overview - Iza-bren (BL-B01D1) is designed to target both EGFR and HER3, which are associated with cancer cell proliferation and survival, utilizing a dual mechanism of action to reduce cancer cell growth [8]